Zobrazeno 1 - 10
of 245
pro vyhledávání: '"György, Vereb"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
CAR T cell therapies face challenges in combating solid tumors due to their single-target approach, which becomes ineffective if the targeted antigen is absent or lost. Universal CAR T cells (UniCAR Ts) provide a promising solution by utilizing molec
Externí odkaz:
https://doaj.org/article/a8964f6b110844eb8baf8db59068311f
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract The actual interaction between signaling species in cellular processes is often more important than their expression levels. Förster resonance energy transfer (FRET) is a popular tool for studying molecular interactions, since it is highly
Externí odkaz:
https://doaj.org/article/01884f0f40104be2a06fe74f594bcc64
Autor:
Markus Barden, Astrid Holzinger, Lukas Velas, Marianna Mezősi-Csaplár, Árpád Szöőr, György Vereb, Gerhard J. Schütz, Andreas A. Hombach, Hinrich Abken
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
In engineered T cells the CAR is co-expressed along with the physiological TCR/CD3 complex, both utilizing the same downstream signaling machinery for T cell activation. It is unresolved whether CAR-mediated T cell activation depends on the presence
Externí odkaz:
https://doaj.org/article/e06e8704a97446f89d093d4b3e77ab95
Autor:
István Rebenku, Ferenc A. Bartha, Tamás Katona, Barbara Zsebik, Géza Antalffy, Lili Takács, Béla Molnár, György Vereb
Publikováno v:
Cytometry Part A. 103:198-207
The emergence and fast advance of digital pathology allows the acquisition, digital storage, interactive recall and analysis of morphology at the tissue level. When applying immunohistochemistry, it also affords the correlation of morphology with the
Autor:
Eliza Guti, Zsolt Regdon, Isotta Sturniolo, Alexandra Kiss, Katalin Kovács, Máté Demény, Árpád Szöőr, György Vereb, János Szöllősi, Csaba Hegedűs, Zsuzsanna Polgár, László Virág
Publikováno v:
Cancer Immunology, Immunotherapy. 71:2151-2168
Despite recent advances in the development of novel personalized therapies, breast cancer continues to challenge physicians with resistance to various advanced therapies. The anticancer action of the anti-HER2 antibody, trastuzumab, involves antibody
Autor:
Mihály Cserepes, Györgyi A. Nelhűbel, Mónika Meilinger-Dobra, Adrienn Herczeg, Dóra Türk, Zita Hegedűs, Laura Svajda, Erzsébet Rásó, Andrea Ladányi, Kristóf György Csikó, István Kenessey, Árpád Szöőr, György Vereb, Éva Remenár, József Tóvári
Publikováno v:
Cancers; Volume 14; Issue 10; Pages: 2407
Background: Head and neck squamous cell carcinomas (HNSCCs) are among the most abundant malignancies worldwide. Patients with recurrent/metastatic disease undergo combination chemotherapy containing cetuximab, the monoclonal antibody used against the
Autor:
Christian H. Wetzel, Hartmut Goldschmidt, Vladimir M. Milenkovic, Mark Berneburg, Mathias Witzens-Harig, György Vereb, Ayse Nur Menevse, Arpad Szoor, Michael Boutros, Antonio Sorrentino, Chih-Yeh Chen, Anchana Rathinasamy, Philipp Beckhove, Sebastian Haferkamp, Klaus G. Griewank, Martin Ehrenschwender, Gertrud Knoll, Tillmann Michels, Madlen Ditz, Valentina Volpin, Anja Seckinger, Dirk Hose, Nisit Khandelwal
Publikováno v:
Cancer Immunology Research. 8:1163-1179
The success of cancer immunotherapy is limited by resistance to immune checkpoint blockade. We therefore conducted a genetic screen to identify genes that mediated resistance against CTLs in anti–PD-L1 treatment–refractory human tumors. Using PD-
Publikováno v:
Applied microbiology and biotechnology. 106(11)
Abstract While phototoxicity can be a useful therapeutic modality not only for eliminating malignant cells but also in treating fungal infections, mycologists aiming to observe morphological changes or molecular events in fungi, especially when long
Publikováno v:
Cancers
Volume 13
Issue 17
Cancers, Vol 13, Iss 4301, p 4301 (2021)
Volume 13
Issue 17
Cancers, Vol 13, Iss 4301, p 4301 (2021)
Correlative studies of clinical studies for hematological malignancies have implicated that less differentiated, CD8+-dominant CAR T cell products have greater antitumor activity. Here, we have investigated whether the differentiation status of CAR T